Biglycan: A Multivalent Proteoglycan Providing Structure and Signals

Journal of Histochemistry and Cytochemistry

Volumn 60, Issue 12, 2012, Pages 963-975

  Nastase, Madalina V ^a   Young, Marian F ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

bone; Duchenne's muscular dystrophy; extracellular matrix; inflammasome; inflammation; proteoglycan; sepsis; skeletal muscle; TGF ; Toll like receptor; Wnt

Indexed keywords

AGRIN; BETA CATENIN; BIGLYCAN; COLLAGENASE 3; CRYOPYRIN; CXCL13 CHEMOKINE; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PERLECAN; PROCOLLAGEN C PROTEINASE; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; EXTRACELLULAR MATRIX; GRANULATION TISSUE; INFLAMMATION; INNATE IMMUNITY; MUSCULAR DYSTROPHY; NONHUMAN; OSTEOBLAST; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; X CHROMOSOME; ANIMAL; BONE DEVELOPMENT; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; BIGLYCAN; CARRIER PROTEINS; EXTRACELLULAR MATRIX; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; MUSCULAR DYSTROPHIES; OSTEOGENESIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84873028647     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155412456380     Document Type: Article

References (125)

1. Ameen V,Robson LG.Experimental models of Duchenne muscular dystrophy: relationship with cardiovascular disease.Open Cardiovasc Med J. 2010;4:265-277.
2. Amenta AR,Creely HE,Mercado ML,Hagiwara H,Mckechnie BA,Lechner BE,Rossi SG,Wang Q,Owens RT,Marrero E, et al.Biglycan is an extracellular MuSK binding protein important for synapse stability.J Neurosci. 2012;32:2324-2334.
3. Amenta AR,Yilmaz A,Bogdanovich S,Mckechnie BA,Abedi M,Khurana TS,Fallon JR.Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice.Proc Natl Acad Sci U S A. 2011;108:762-767.
4. Ameye L,Aria D,Jepsen K,Oldberg A,Xu T,Young MF.Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis.FASEB J. 2002;16:673-680.
5. Ameye L,Young MF.Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases.Glycobiology. 2002;12:107R-1016R.
6. Antipova O,Orgel JP.Non-enzymatic decomposition of collagen fibers by a biglycan antibody and a plausible mechanism for rheumatoid arthritis.PLoS One. 2012;7:e32241.
7. Babelova A,Moreth K,Tsalastra-Greul W,Zeng-Brouwers J,Eickelberg O,Young MF,Bruckner P,Pfeilschifter J,Schaefer RM,Grone HJ, et al.Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors.J Biol Chem. 2009;284:24035-24048.
8. Bellucci C,Lilli C,Baroni T,Parnetti L,Sorbi S,Emiliani C,Lumare E,Calabresi P,Balloni S,Bodo M.Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease.Mol Med. 2007;13:542-550.
9. Berendsen AD,Fisher LW,Kilts TM,Owens RT,Robey PG,Gutkind JS,Young MF.Modulation of canonical Wnt signaling by the extracellular matrix component biglycan.Proc Natl Acad Sci U S A. 2011;108:17022-17027.
10. Bi Y,Ehirchiou D,Kilts TM,Inkson CA,Embree MC,Sonoyama W,Li L,Leet AI,Seo BM,Zhang L, et al.Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche.Nat Med. 2007;13:1219-1227.
11. Bi Y,Stuelten CH,Kilts T,Wadhwa S,Iozzo RV,Robey PG,Chen XD,Young MF.Extracellular matrix proteoglycans control the fate of bone marrow stromal cells.J Biol Chem. 2005;280:30481-30489.
12. Bianco P,Fisher LW,Young MF,Termine JD,Robey PG.Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues.J Histochem Cytochem. 1990;38:1549-1563.
13. Boivin WA,Shackleford M,Vanden Hoek A,Zhao H,Hackett TL,Knight DA,Granville DJ.Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1.PLoS ONE. 2012;7:e33163.
14. Bolton K,Segal D,Walder K.The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes.Biologics. 2012;6:67-72.
15. Border WA,Okuda S,Languino LR,Ruoslahti E.Transforming growth factor-beta regulates production of proteoglycans by mesangial cells.Kidney Int. 1990;37:689-695.
16. Bosse A,Schwarz K,Vollmer E,Kresse H.Divergent and co-localization of the two small proteoglycans decorin and proteoglycan-100 in human skeletal tissues and tumors.J Histochem Cytochem. 1993;41:13-19.
17. Boukpessi T,Menashi S,Camoin L,Tencate JM,Goldberg M,Chaussain-Miller C.The effect of stromelysin-1 (MMP-3) on non-collagenous extracellular matrix proteins of demineralized dentin and the adhesive properties of restorative resins.Biomaterials. 2008;29:4367-4373.
18. Bowe MA,Mendis DB,Fallon JR.The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle.J Cell Biol. 2000;148:801-810.
19. Brandan E,Cabello-Verrugio C,Vial C.Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy.Matrix Biol. 2008;27:700-708.
20. Brown S,Melrose J,Caterson B,Roughley P,Eisenstein SM,Roberts S.A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs.Eur Spine J. 2012;21:S154-S159.
21. Brussee V,Tardif F,Tremblay JP.Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice.Neuromuscul Disord. 1997;7:487-492.
22. Calabrese GC,Gazzaniga S,Oberkersch R,Wainstok R.Decorin and biglycan expression: its relation with endothelial heterogeneity.Histol Histopathol. 2011;26:481-490.
23. Campbell PH,Hunt DL,Jones Y,Harwood F,Amiel D,Omens JH,Mcculloch AD.Effects of biglycan deficiency on myocardial infarct structure and mechanics.Mol Cell Biomech. 2008;5:27-35.
24. Casar JC,Mckechnie BA,Fallon JR,Young MF,Brandan E.Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice.Dev Biol. 2004;268:358-371.
25. Chen GY,Nunez G.Sterile inflammation: sensing and reacting to damage.Nat Rev Immunol. 2010;10:826-837.
26. Chen XD,Fisher LW,Robey PG,Young MF.The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation.FASEB J. 2004;18:948-958.
27. Chen XD,Shi S,Xu T,Robey PG,Young MF.Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells.J Bone Miner Res. 2002;17:331-340.
28. Choi HU,Johnson TL,Pal S,Tang LH,Rosenberg L,Neame PJ.Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography.J Biol Chem. 1989;264:2876-2884.
29. Corsi A,Xu T,Chen XD,Boyde A,Liang J,Mankani M,Sommer B,Iozzo RV,Eichstetter I,Robey PG, et al.Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues.J Bone Miner Res. 2002;17:1180-1189.
30. Coulson-Thomas VJ,Coulson-Thomas YM,Gesteira TF,De Paula CA,Mader AM,Waisberg J,Pinhal MA,Friedl A,Toma L,Nader HB.Colorectal cancer desmoplastic reaction up-regulates collagen synthesis and restricts cancer cell invasion.Cell Tissue Res. 2011;346:223-236.
31. de Kluijver J,Schrumpf JA,Evertse CE,Sont JK,Roughley PJ,Rabe KF,Hiemstra PS,Mauad T,Sterk PJ.Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma.Clin Exp Allergy. 2005;35:1361-1369.
32. Derbali H,Bosse Y,Cote N,Pibarot P,Audet A,Pepin A,Arsenault B,Couture C,Despres JP,Mathieu P.Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2.Am J Pathol. 2010;176:2638-2645.
33. Desnoyers L,Arnott D,Pennica D.WISP-1 binds to decorin and biglycan.J Biol Chem. 2001;276:47599-47607.
34. Dinarello CA.Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.Blood. 2011;117:3720-3732.
35. Douglas T,Heinemann S,Bierbaum S,Scharnweber D,Worch H.Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan.Biomacromolecules. 2006;7:2388-2393.
36. Embree MC,Kilts TM,Ono M,Inkson CA,Syed-Picard F,Karsdal MA,Oldberg A,Bi Y,Young MF.Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis.Am J Pathol. 2010;176:812-826.
37. Fadic R,Mezzano V,Alvarez K,Cabrera D,Holmgren J,Brandan E.Increase in decorin and biglycan in Duchenne muscular dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease.J Cell Mol Med. 2006;10:758-769.
38. Fisher LW,Termine JD,Dejter SW Jr,Whitson SW,Yanagishita M,Kimura JH,Hascall VC,Kleinman HK,Hassell JR,Nilsson B.Proteoglycans of developing bone.J Biol Chem. 1983;258:6588-6594.
39. French DM,Kaul RJ,D'souza AL,Crowley CW,Bao M,Frantz GD,Filvaroff EH,Desnoyers L.WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair.Am J Pathol. 2004;165:855-867.
40. Gressner AM.Activation of proteoglycan synthesis in injured liver-a brief review of molecular and cellular aspects.Eur J Clin Chem Clin Biochem. 1994;32:225-237.
41. Gu X,Ma Y,Xiao J,Zheng H,Song C,Gong Y,Xing X.Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers.Clin Exp Med. 2012;12:195-199.
42. Hakkinen L,Westermarck J,Kahari VM,Larjava H.Human granulation-tissue fibroblasts show enhanced proteoglycan gene expression and altered response to TGF-beta 1.J Dent Res. 1996;75:1767-1778.
43. Heegaard AM,Corsi A,Danielsen CC,Nielsen KL,Jorgensen HL,Riminucci M,Young MF,Bianco P.Biglycan deficiency causes spontaneous aortic dissection and rupture in mice.Circulation. 2007;115:2731-2738.
44. Hildebrand A,Romaris M,Rasmussen LM,Heinegard D,Twardzik DR,Border WA,Ruoslahti E.Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.Biochem J. 1994;302 (Pt 2): 527-534.
45. Hogemann B,Edel G,Schwarz K,Krech R,Kresse H.Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver.Pathol Res Pract. 1997;193:747-751.
46. Hunzelmann N,Anders S,Sollberg S,Schonherr E,Krieg T.Co-ordinate induction of collagen type I and biglycan expression in keloids.Br J Dermatol. 1996;135:394-399.
47. Hwang JY,Johnson PY,Braun KR,Hinek A,Fischer JW,O'Brien KD,Starcher B,Clowes AW,Merrilees MJ,Wight TN.Retrovirally mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointimae after vascular injury.Am J Pathol. 2008;173:1919-1928.
48. Inkson CA,Ono M,Bi Y,Kuznetsov SA,Fisher LW,Young MF.The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells.Cells Tissues Organs. 2009;189:153-157.
49. Iozzo RV,Schaefer L.Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010;277:3864-3875.
50. Johnson GB,Brunn GJ,Kodaira Y,Platt JL.Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.J Immunol. 2002;168:5233-5239.
51. Johnstone B,Markopoulos M,Neame P,Caterson B.Identification and characterization of glycanated and non-glycanated forms of biglycan and decorin in the human intervertebral disc.Biochem J. 1993;292 (Pt 3): 661-666.
52. Kalamajski S,Oldberg A.The role of small leucine-rich proteoglycans in collagen fibrillogenesis.Matrix Biol. 2010;29:248-253.
53. Kikuchi A,Tomoyasu H,Kido I,Takahashi K,Tanaka A,Nonaka I,Iwakami N,Kamo I.Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells.J Neuroimmunol. 2000;106:78-86.
54. Kim S,Takahashi H,Lin WW,Descargues P,Grivennikov S,Kim Y,Luo JL,Karin M.Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.Nature. 2009;457:102-106.
55. Kitaya K,Yasuo T.Dermatan sulfate proteoglycan biglycan as a potential selectin L/CD44 ligand involved in selective recruitment of peripheral blood CD16(-) natural killer cells into human endometrium.J Leukoc Biol. 2009;85:391-400.
56. Krull NB,Zimmermann T,Gressner AM.Spatial and temporal patterns of gene expression for the proteoglycans biglycan and decorin and for transforming growth factor-beta 1 revealed by in situ hybridization during experimentally induced liver fibrosis in the rat.Hepatology. 1993;18:581-589.
57. Kuroda M,Sasamura H,Kobayashi E,Shimizu-Hirota R,Nakazato Y,Hayashi M,Saruta T.Glomerular expression of biglycan and decorin and urinary levels of decorin in primary glomerular disease.Clin Nephrol. 2004;61:7-16.
58. Lam V,Takechi R,Pallebage-Gamarallage MM,Galloway S,Mamo JC.Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease.Neurosci Lett. 2011;492:160-164.
59. Leemans JC,Butter LM,Pulskens WP,Teske GJ,Claessen N,Van Der Poll T,Florquin S.The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury.PLoS One. 2009;4:e5704.
60. Luz MA,Marques MJ,Santo Neto H.Impaired regeneration of dystrophin-deficient muscle fibers is caused by exhaustion of myogenic cells.Braz J Med Biol Res. 2002;35:691-695.
61. McBride OW,Fisher LW,Young MF.Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively.Genomics. 1990;6:219-225.
62. Mercado ML,Amenta AR,Hagiwara H,Rafii MS,Lechner BE,Owens RT,Mcquillan DJ,Froehner SC,Fallon JR.Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS.FASEB J. 2006;20:1724-1726.
63. Merline R,Moreth K,Beckmann J,Nastase MV,Zeng-Brouwers J,Tralhao JG,Lemarchand P,Pfeilschifter J,Schaefer RM,Iozzo RV, et alSci Signal. ra75; 2011:.
64. Merline R,Schaefer RM,Schaefer L.The matricellular functions of small leucine-rich proteoglycans (SLRPs).J Cell Commun Signal. 2009;3:323-335.
65. Meyer DH,Krull N,Dreher KL,Gressner AM.Biglycan and decorin gene expression in normal and fibrotic rat liver: cellular localization and regulatory factors.Hepatology. 1992;16:204-216.
66. Midwood K,Sacre S,Piccinini AM,Inglis J,Trebaul A,Chan E,Drexler S,Sofat N,Kashiwagi M,Orend G, et al.Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.Nat Med. 2009;15:774-780.
67. Miguez PA,Terajima M,Nagaoka H,Mochida Y,Yamauchi M.Role of glycosaminoglycans of biglycan in BMP-2 signaling.Biochem Biophys Res Commun. 2011;405:262-266.
68. Mintz MB,Sowers R,Brown KM,Hilmer SC,Mazza B,Huvos AG,Meyers PA,Lafleur B,Mcdonough WS,Henry MM, et al.An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.Cancer Res. 2005;65:1748-1754.
69. Mochida Y,Parisuthiman D,Yamauchi M.Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation.Adv Exp Med Biol. 2006;585:101-113.
70. Mohan H,Krumbholz M,Sharma R,Eisele S,Junker A,Sixt M,Newcombe J,Wekerle H,Hohlfeld R,Lassmann H, et al.Extracellular matrix in multiple sclerosis lesions: fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells.Brain Pathol. 2010;20:966-975.
71. Monfort J,Tardif G,Reboul P,Mineau F,Roughley P,Pelletier JP,Martel-Pelletier J.Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site.Arthritis Res Ther. 2006;8:R26.
72. Moreno M,Munoz R,Aroca F,Labarca M,Brandan E,Larrain J.Biglycan is a new extracellular component of the Chordin-BMP4 signaling pathway.EMBO J. 2005;24:1397-1405.
73. Moreth K,Brodbeck R,Babelova A,Gretz N,Spieker T,Zeng-Brouwers J,Pfeilschifter J,Young MF,Schaefer RM,Schaefer L.The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.J Clin Invest. 2010;120:4251-4272.
74. Moreth K,Iozzo RV,Schaefer L.Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation.Cell Cycle. 2012;11:2084-2091.
75. Mozes MM,Bottinger EP,Jacot TA,Kopp JB.Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice.J Am Soc Nephrol. 1999;10:271-280.
76. Nakashima Y,Fujii H,Sumiyoshi S,Wight TN,Sueishi K.Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration.Arterioscler Thromb Vasc Biol. 2007;27:1159-1165.
77. Nihlberg K,Andersson-Sjoland A,Tufvesson E,Erjefalt JS,Bjermer L,Westergren-Thorsson G.Altered matrix production in the distal airways of individuals with asthma.Thorax. 2010;65:670-676.
78. Parisuthiman D,Mochida Y,Duarte WR,Yamauchi M.Biglycan modulates osteoblast differentiation and matrix mineralization.J Bone Miner Res. 2005;20:1878-1886.
79. Pfeilschifter J.Nitric oxide triggers the expression of proinflammatory and protective gene products in mesangial cells and the inflamed glomerulus.Nephrol Dial Transplant. 2002;17:347-348.
80. Pinelli V,Marchica CL,Ludwig MS.Allergen-induced asthma in C57Bl/6 mice: hyper-responsiveness, inflammation and remodelling.Respir Physiol Neurobiol. 2009;169:36-43.
81. Pini L,Hamid Q,Shannon J,Lemelin L,Olivenstein R,Ernst P,Lemiere C,Martin JG,Ludwig MS.Differences in proteoglycan deposition in the airways of moderate and severe asthmatics.Eur Respir J. 2007;29:71-77.
82. Polgar A,Falus A,Koo E,Ujfalussy I,Sesztak M,Szuts I,Konrad K,Hodinka L,Bene E,Meszaros G, et al.Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases.Rheumatology (Oxford). 2003;42:522-527.
83. Popovic ZV,Wang S,Papatriantafyllou M,Kaya Z,Porubsky S,Meisner M,Bonrouhi M,Burgdorf S,Young MF,Schaefer L, et al.The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis.J Immunol. 2011;187:6217-6226.
84. Rafii MS,Hagiwara H,Mercado ML,Seo NS,Xu T,Dugan T,Owens RT,Hook M,Mcquillan DJ,Young MF, et al.Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.J Cell Physiol. 2006;209:439-447.
85. Rathinam VA,Vanaja SK,Fitzgerald KA.Regulation of inflammasome signaling.Nat Immunol. 2012;13:333-342.
86. Reinboth B,Hanssen E,Cleary EG,Gibson MA.Molecular interactions of biglycan and decorin with elastic fiber components: biglycan forms a ternary complex with tropoelastin and microfibril-associated glycoprotein 1.J Biol Chem. 2002;277:3950-3957.
87. Roughley PJ,White RJ.Dermatan sulphate proteoglycans of human articular cartilage: the properties of dermatan sulphate proteoglycans I and II.Biochem J. 1989;262:823-827.
88. Roughley PJ,White RJ,Magny MC,Liu J,Pearce RH,Mort JS.Non-proteoglycan forms of biglycan increase with age in human articular cartilage.Biochem J. 1993;295 (Pt 2): 421-426.
89. Schaefer L.Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol. 2010;10:185-190.
90. Schaefer L.Small leucine-rich proteoglycans in kidney disease.J Am Soc Nephrol. 2011;22:1200-1207.
91. Schaefer L,Babelova A,Kiss E,Hausser HJ,Baliova M,Krzyzankova M,Marsche G,Young MF,Mihalik D,Gotte M, et al.The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.J Clin Invest. 2005;115:2223-2233.
92. Schaefer L,Grone HJ,Raslik I,Robenek H,Ugorcakova J,Budny S,Schaefer RM,Kresse H.Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican.Kidney Int. 2000;58:1557-1568.
93. Schaefer L,Hausser H,Altenburger M,Ugorcakova J,August C,Fisher LW,Schaefer RM,Kresse H.Decorin, biglycan and their endocytosis receptor in rat renal cortex.Kidney Int. 1998;54:1529-1541.
94. Schaefer L,Macakova K,Raslik I,Micegova M,Grone HJ,Schonherr E,Robenek H,Echtermeyer FG,Grassel S,Bruckner P, et al.Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction.Am J Pathol. 2002;160:1181-1191.
95. Schaefer L,Raslik I,Grone HJ,Schonherr E,Macakova K,Ugorcakova J,Budny S,Schaefer RM,Kresse H.Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin.FASEB J. 2001;15:559-561.
96. Schaefer L,Iozzo RV.Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction.J Biol Chem. 2008;283:21305-21309.
97. Schaefer L,Iozzo RV.Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation.Curr Opin Genet Dev. 2012;22:56-57.
98. Schaefer L,Schaefer RM.Proteoglycans: from structural compounds to signaling molecules.Cell Tissue Res. 2010;339:237-246.
99. Schonherr E,Witsch-Prehm P,Harrach B,Robenek H,Rauterberg J,Kresse H.Interaction of biglycan with type I collagen.J Biol Chem. 1995;270:2776-2783.
100. Scott IC,Imamura Y,Pappano WN,Troedel JM,Recklies AD,Roughley PJ,Greenspan DS.Bone morphogenetic protein-1 processes probiglycan.J Biol Chem. 2000;275:30504-30511.
101. Sjoberg AP,Manderson GA,Morgelin M,Day AJ,Heinegard D,Blom AM.Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation.Mol Immunol. 2009;46:830-839.
102. Skalen K,Gustafsson M,Rydberg EK,Hulten LM,Wiklund O,Innerarity TL,Boren J.Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.Nature. 2002;417:750-754.
103. Sokolove J,Bromberg R,Deane KD,Lahey LJ,Derber LA,Chandra PE,Edison JD,Gilliland WR,Tibshirani RJ,Norris JM, et al.Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis.PLoS One. 2012;7:e35296.
104. Termeer C,Benedix F,Sleeman J,Fieber C,Voith U,Ahrens T,Miyake K,Freudenberg M,Galanos C,Simon JC.Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4.J Exp Med. 2002;195:99-111.
105. Theocharis AD,Skandalis SS,Tzanakakis GN,Karamanos NK.Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.FEBS J. 2010;277:3904-3923.
106. Thompson J,Wilson P,Brandewie K,Taneja D,Schaefer L,Mitchell B,Tannock LR.Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy.Am J Pathol. 2011;179:1179-1187.
107. Tschopp J,Schroder K.NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210-215.
108. Tufvesson E,Westergren-Thorsson G.Tumour necrosis factor-alpha interacts with biglycan and decorin.FEBS Lett. 2002;530:124-128.
109. Ungefroren H,Gellersen B,Krull NB,Kalthoff H.Biglycan gene expression in the human leiomyosarcoma cell line SK-UT-1: basal and protein kinase A-induced transcription involves binding of Sp1-like/Sp3 proteins in the proximal promoter region.J Biol Chem. 1998;273:29230-29240.
110. Ungefroren H,Krull NB.Transcriptional regulation of the human biglycan gene.J Biol Chem. 1996;271:15787-15795.
111. Venkatesan N,Siddiqui S,Jo T,Martin JG,Ludwig MS.Allergen-induced airway remodeling in brown Norway rats: structural and metabolic changes in glycosaminoglycans.Am J Respir Cell Mol Biol. 2012;46:96-105.
112. Wadhwa S,Bi Y,Ortiz AT,Embree MC,Kilts T,Iozzo R,Opperman LA,Young MF.Impaired posterior frontal sutural fusion in the biglycan/decorin double deficient mice.Bone. 2007;40:861-866.
113. Wadhwa S,Embree M,Ameye L,Young MF.Mice deficient in biglycan and fibromodulin as a model for temporomandibular joint osteoarthritis.Cells Tissues Organs. 2005;181:136-143.
114. Wadhwa S,Embree MC,Bi Y,Young MF.Regulation, regulatory activities, and function of biglycan.Crit Rev Eukaryot Gene Expr. 2004;14:301-315.
115. Wang B,Li GX,Zhang SG,Wang Q,Wen YG,Tang HM,Zhou CZ,Xing AY,Fan JW,Yan DW, et al.Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer.Exp Biol Med (Maywood). 2011;236:1247-1253.
116. Wang S,Schmaderer C,Kiss E,Schmidt C,Bonrouhi M,Porubsky S,Gretz N,Schaefer L,Kirschning CJ,Popovic ZV, et al.Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling.Dis Model Mech. 2010;3:92-103.
117. Westergren-Thorsson G,Hernnas J,Sarnstrand B,Oldberg A,Heinegard D,Malmstrom A.Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats.J Clin Invest. 1993;92:632-637.
118. Westermann D,Mersmann J,Melchior A,Freudenberger T,Petrik C,Schaefer L,Lullmann-Rauch R,Lettau O,Jacoby C,Schrader J, et al.Biglycan is required for adaptive remodeling after myocardial infarction.Circulation. 2008;117:1269-1276.
119. Wu H,Chen G,Wyburn KR,Yin J,Bertolino P,Eris JM,Alexander SI,Sharland AF,Chadban SJ.TLR4 activation mediates kidney ischemia/reperfusion injury.J Clin Invest. 2007;117:2847-2859.
120. Xu T,Bianco P,Fisher LW,Longenecker G,Smith E,Goldstein S,Bonadio J,Boskey A,Heegaard AM,Sommer B, et al.Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice.Nat Genet. 1998;20:78-82.
121. Young MF,Bi Y,Ameye L,Chen XD.Biglycan knockout mice: new models for musculoskeletal diseases.Glycoconj J. 2002;19:257-262.
122. Young MF,Bi Y,Ameye L,Xu T,Wadhwa S,Heegaard A,Kilts T,Chen XD.Small leucine-rich proteoglycans in the aging skeleton.J Musculoskelet Neuronal Interact. 2006;6:364-365.
123. Zanotti S,Negri T,Cappelletti C,Bernasconi P,Canioni E,Di Blasi C,Pegoraro E,Angelini C,Ciscato P,Prelle A, et al.Decorin and biglycan expression is differentially altered in several muscular dystrophies.Brain. 2005;128:2546-2555.
124. Zhang G,Chen S,Goldoni S,Calder BW,Simpson HC,Owens RT,Mcquillan DJ,Young MF,Iozzo RV,Birk DE.Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan.J Biol Chem. 2009;284:8888-8897.
125. Zhou L,Lu H.Targeting fibrosis in Duchenne muscular dystrophy.J Neuropathol Exp Neurol. 2010;69:771-776.